Your selection
Research / 06.02.2026
Professorship awarded to Mina Gouti
Mina Gouti has been awarded a professorship at Charité – Universitätsmedizin Berlin. The appointment will strengthen her pioneering organoid research at the Max Delbrück Center and deepen collaboration with clinicians to advance personalized medicine.
Dr. Mina Gouti, Group Leader of the Stem Cell Modeling of Development and Disease lab at the Max Delbrück Center, has been appointed W3 Professor of Complex Organoid Models for Personalized Medicine in the Medical Faculty, Charité – Universitätsmedizin Berlin. The permanent position recognizes her achievements in developing advanced organoid systems to understand how specific types of spinal cord neurons and skeletal muscle cells grow in space and time during development.
“This professorship will enable my team to fully leverage Berlin’s exceptional biomedical ecosystem and to work closely with clinicians at Charité to create complex organoids for personalized medicine,” Gouti says. This close interaction is essential for translating patient-derived organoid models into clinically relevant insights.”
The Gouti lab has developed three-dimensional neuromuscular organoids from human pluripotent stem cells that replicate key features of spinal cord neurons and skeletal muscle – providing powerful platforms for studying neuromuscular diseases such as spinal muscular atrophy and amyotrophic lateral sclerosis, and for drug screening. Such organoids can also be grown from cells derived from individual patients to model their specific disease.
The position reflects a shared vision between the Max Delbrück Center and Charité to accelerate translational research through fostering closer collaboration between clinicians researchers. “We now have the long-term perspective required to develop complex, functional organoids as predictive platforms for personalized medicine and early disease interception,” says Gouti. “We hope our research will lead to better health outcomes not only for people with neuromuscular diseases, but also those at high risk of developing them.”
Text: Gunjan Sinha
Further information
Overview News
News Buch Berlin
OMEICOS’ OMT-28 Headed for Phase 3 in Primary Mitochondrial Diseases (PMD) Following Positive End-of-Phase 2 Meeting with the FDA
OMEICOS, a late-stage clinical biopharmaceutical company developing first-in-class small-molecule therapeutics for mitochondrial and inflammatory disorders, today announced the successful completion o...
more ...A single cocaine dose alters mouse brain cells
Researchers led by Ana Pombo have found that just one exposure to the drug can create changes in mouse brain cells that persist for at least two weeks. Their findings were presented at the Federation ...
more ...How the skin distinguishes cool from warm
Researchers in the lab of James Poulet have uncovered how the nervous system senses cool and warm temperatures. The findings, published in “Neuron” challenge a long-standing view of temperature sensi...
more ...Events Buch Berlin
31.07.2026, 15:00
Ferienprogramm in der Stadtbibliothek: Experimente zum Thema Fliegen
Entdecke die Geheimnisse des Fliegens!
more ...01.08.2026, 15:00
Gartengalerie Karow
Das Künstlerpaar Marion Friedrich (Malerei) und Dirk Motzkus (Skulpturen) öffnen ihre künstlerische Werkstatt für Interessierte
more ...